No Cover Image

Journal article 494 views 61 downloads

Biologic use in psoriatic arthritis and ankylosing spondylitis patients: a descriptive epidemiological study using linked, routine data in Wales, UK

Roxanne Cooksey Orcid Logo, Muhammad Azizur Rahman, Jonathan Kennedy, Sinead Brophy Orcid Logo, Ernest Choy

Rheumatology Advances in Practice, Volume: 5, Issue: 2, Start page: rkab042

Swansea University Authors: Roxanne Cooksey Orcid Logo, Jonathan Kennedy, Sinead Brophy Orcid Logo

  • 58661.pdf

    PDF | Version of Record

    Copyright: The Author(s) 2021.This is an Open Access article distributed under the terms of the Creative Commons Attribution License

    Download (252.72KB)

Check full text

DOI (Published version): 10.1093/rap/rkab042

Abstract

ObjectivesPsA and AS are chronic diseases associated with significant morbidities. National and international management guidelines include treatment with biologic therapies to improve outcomes and quality of life. There are limited real-world data on the patients’ journey from symptom onset to diag...

Full description

Published in: Rheumatology Advances in Practice
ISSN: 2514-1775 2514-1775
Published: Oxford University Press (OUP) 2021
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa58661
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2021-11-15T11:02:04Z
last_indexed 2021-12-01T04:18:39Z
id cronfa58661
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2021-11-30T16:45:25.6596906</datestamp><bib-version>v2</bib-version><id>58661</id><entry>2021-11-15</entry><title>Biologic use in psoriatic arthritis and ankylosing spondylitis patients: a descriptive epidemiological study using linked, routine data in Wales, UK</title><swanseaauthors><author><sid>df63826249b712dcb03cb0161d0f3daf</sid><ORCID>0000-0002-6763-9373</ORCID><firstname>Roxanne</firstname><surname>Cooksey</surname><name>Roxanne Cooksey</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>08163d1f58d7fefcb1c695bcc2e0ef68</sid><ORCID/><firstname>Jonathan</firstname><surname>Kennedy</surname><name>Jonathan Kennedy</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>84f5661b35a729f55047f9e793d8798b</sid><ORCID>0000-0001-7417-2858</ORCID><firstname>Sinead</firstname><surname>Brophy</surname><name>Sinead Brophy</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2021-11-15</date><deptcode>HDAT</deptcode><abstract>ObjectivesPsA and AS are chronic diseases associated with significant morbidities. National and international management guidelines include treatment with biologic therapies to improve outcomes and quality of life. There are limited real-world data on the patients&#x2019; journey from symptom onset to diagnosis and treatment in the UK. We use real-life, linked health data to explore patient pathways and the impact of biologics on patient outcomes.MethodsData from the Secure Anonymised Information Linkage databank in Wales were used to assess diagnosis and treatment of patients &#x2265;18&#x2009;years of age with at least one International Classification of Diseases, Tenth Revision code present for PsA/AS in rheumatology clinic data and at least one Read code present in primary care records. We investigated the use of biologics while exploring demographics, comorbidities and surgical procedures of 641 AS patients and 1312 PsA patients.ResultsAS patients were significantly younger at diagnosis and were predominantly male. The average time from presenting symptoms to diagnosis of AS and PsA was 7.9 (S.D. 5.5) and 9.3 (S.D. 5.5)&#x2009;years, respectively. The proportion of patients receiving biologic treatment was significantly higher in AS (46%) compared with PsA patients (28.8%); of these, 23.1% of AS and 22.2% of PsA patients stopped/switched a biologic. There was a significant reduction in primary care involvement, sick notes and disability living allowance for both AS and PsA patients following biologic initiation.ConclusionThis real-world descriptive study confirms that patients treated with biologics have reduced disability and time off work despite being initiated &#x223C;13&#x2009;years after the first symptoms and 6&#x2009;years after diagnosis.</abstract><type>Journal Article</type><journal>Rheumatology Advances in Practice</journal><volume>5</volume><journalNumber>2</journalNumber><paginationStart>rkab042</paginationStart><paginationEnd/><publisher>Oxford University Press (OUP)</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>2514-1775</issnPrint><issnElectronic>2514-1775</issnElectronic><keywords>psoriatic arthritis, ankylosing spondylitis, biologics, outcomes, treatment pathways, electronic health records</keywords><publishedDay>27</publishedDay><publishedMonth>6</publishedMonth><publishedYear>2021</publishedYear><publishedDate>2021-06-27</publishedDate><doi>10.1093/rap/rkab042</doi><url/><notes/><college>COLLEGE NANME</college><department>Health Data Science</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>HDAT</DepartmentCode><institution>Swansea University</institution><apcterm/><funders>Novartis Pharmaceuticals (grant 513540 to E.C.)</funders><lastEdited>2021-11-30T16:45:25.6596906</lastEdited><Created>2021-11-15T10:57:20.6949247</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Roxanne</firstname><surname>Cooksey</surname><orcid>0000-0002-6763-9373</orcid><order>1</order></author><author><firstname>Muhammad Azizur</firstname><surname>Rahman</surname><order>2</order></author><author><firstname>Jonathan</firstname><surname>Kennedy</surname><orcid/><order>3</order></author><author><firstname>Sinead</firstname><surname>Brophy</surname><orcid>0000-0001-7417-2858</orcid><order>4</order></author><author><firstname>Ernest</firstname><surname>Choy</surname><order>5</order></author></authors><documents><document><filename>58661__21531__b7d534b33bcd49f4ba8c1a50213db1be.pdf</filename><originalFilename>58661.pdf</originalFilename><uploaded>2021-11-15T10:59:17.7125267</uploaded><type>Output</type><contentLength>258790</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>Copyright: The Author(s) 2021.This is an Open Access article distributed under the terms of the Creative Commons Attribution License</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2021-11-30T16:45:25.6596906 v2 58661 2021-11-15 Biologic use in psoriatic arthritis and ankylosing spondylitis patients: a descriptive epidemiological study using linked, routine data in Wales, UK df63826249b712dcb03cb0161d0f3daf 0000-0002-6763-9373 Roxanne Cooksey Roxanne Cooksey true false 08163d1f58d7fefcb1c695bcc2e0ef68 Jonathan Kennedy Jonathan Kennedy true false 84f5661b35a729f55047f9e793d8798b 0000-0001-7417-2858 Sinead Brophy Sinead Brophy true false 2021-11-15 HDAT ObjectivesPsA and AS are chronic diseases associated with significant morbidities. National and international management guidelines include treatment with biologic therapies to improve outcomes and quality of life. There are limited real-world data on the patients’ journey from symptom onset to diagnosis and treatment in the UK. We use real-life, linked health data to explore patient pathways and the impact of biologics on patient outcomes.MethodsData from the Secure Anonymised Information Linkage databank in Wales were used to assess diagnosis and treatment of patients ≥18 years of age with at least one International Classification of Diseases, Tenth Revision code present for PsA/AS in rheumatology clinic data and at least one Read code present in primary care records. We investigated the use of biologics while exploring demographics, comorbidities and surgical procedures of 641 AS patients and 1312 PsA patients.ResultsAS patients were significantly younger at diagnosis and were predominantly male. The average time from presenting symptoms to diagnosis of AS and PsA was 7.9 (S.D. 5.5) and 9.3 (S.D. 5.5) years, respectively. The proportion of patients receiving biologic treatment was significantly higher in AS (46%) compared with PsA patients (28.8%); of these, 23.1% of AS and 22.2% of PsA patients stopped/switched a biologic. There was a significant reduction in primary care involvement, sick notes and disability living allowance for both AS and PsA patients following biologic initiation.ConclusionThis real-world descriptive study confirms that patients treated with biologics have reduced disability and time off work despite being initiated ∼13 years after the first symptoms and 6 years after diagnosis. Journal Article Rheumatology Advances in Practice 5 2 rkab042 Oxford University Press (OUP) 2514-1775 2514-1775 psoriatic arthritis, ankylosing spondylitis, biologics, outcomes, treatment pathways, electronic health records 27 6 2021 2021-06-27 10.1093/rap/rkab042 COLLEGE NANME Health Data Science COLLEGE CODE HDAT Swansea University Novartis Pharmaceuticals (grant 513540 to E.C.) 2021-11-30T16:45:25.6596906 2021-11-15T10:57:20.6949247 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Roxanne Cooksey 0000-0002-6763-9373 1 Muhammad Azizur Rahman 2 Jonathan Kennedy 3 Sinead Brophy 0000-0001-7417-2858 4 Ernest Choy 5 58661__21531__b7d534b33bcd49f4ba8c1a50213db1be.pdf 58661.pdf 2021-11-15T10:59:17.7125267 Output 258790 application/pdf Version of Record true Copyright: The Author(s) 2021.This is an Open Access article distributed under the terms of the Creative Commons Attribution License true eng http://creativecommons.org/licenses/by/4.0/
title Biologic use in psoriatic arthritis and ankylosing spondylitis patients: a descriptive epidemiological study using linked, routine data in Wales, UK
spellingShingle Biologic use in psoriatic arthritis and ankylosing spondylitis patients: a descriptive epidemiological study using linked, routine data in Wales, UK
Roxanne Cooksey
Jonathan Kennedy
Sinead Brophy
title_short Biologic use in psoriatic arthritis and ankylosing spondylitis patients: a descriptive epidemiological study using linked, routine data in Wales, UK
title_full Biologic use in psoriatic arthritis and ankylosing spondylitis patients: a descriptive epidemiological study using linked, routine data in Wales, UK
title_fullStr Biologic use in psoriatic arthritis and ankylosing spondylitis patients: a descriptive epidemiological study using linked, routine data in Wales, UK
title_full_unstemmed Biologic use in psoriatic arthritis and ankylosing spondylitis patients: a descriptive epidemiological study using linked, routine data in Wales, UK
title_sort Biologic use in psoriatic arthritis and ankylosing spondylitis patients: a descriptive epidemiological study using linked, routine data in Wales, UK
author_id_str_mv df63826249b712dcb03cb0161d0f3daf
08163d1f58d7fefcb1c695bcc2e0ef68
84f5661b35a729f55047f9e793d8798b
author_id_fullname_str_mv df63826249b712dcb03cb0161d0f3daf_***_Roxanne Cooksey
08163d1f58d7fefcb1c695bcc2e0ef68_***_Jonathan Kennedy
84f5661b35a729f55047f9e793d8798b_***_Sinead Brophy
author Roxanne Cooksey
Jonathan Kennedy
Sinead Brophy
author2 Roxanne Cooksey
Muhammad Azizur Rahman
Jonathan Kennedy
Sinead Brophy
Ernest Choy
format Journal article
container_title Rheumatology Advances in Practice
container_volume 5
container_issue 2
container_start_page rkab042
publishDate 2021
institution Swansea University
issn 2514-1775
2514-1775
doi_str_mv 10.1093/rap/rkab042
publisher Oxford University Press (OUP)
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str 1
active_str 0
description ObjectivesPsA and AS are chronic diseases associated with significant morbidities. National and international management guidelines include treatment with biologic therapies to improve outcomes and quality of life. There are limited real-world data on the patients’ journey from symptom onset to diagnosis and treatment in the UK. We use real-life, linked health data to explore patient pathways and the impact of biologics on patient outcomes.MethodsData from the Secure Anonymised Information Linkage databank in Wales were used to assess diagnosis and treatment of patients ≥18 years of age with at least one International Classification of Diseases, Tenth Revision code present for PsA/AS in rheumatology clinic data and at least one Read code present in primary care records. We investigated the use of biologics while exploring demographics, comorbidities and surgical procedures of 641 AS patients and 1312 PsA patients.ResultsAS patients were significantly younger at diagnosis and were predominantly male. The average time from presenting symptoms to diagnosis of AS and PsA was 7.9 (S.D. 5.5) and 9.3 (S.D. 5.5) years, respectively. The proportion of patients receiving biologic treatment was significantly higher in AS (46%) compared with PsA patients (28.8%); of these, 23.1% of AS and 22.2% of PsA patients stopped/switched a biologic. There was a significant reduction in primary care involvement, sick notes and disability living allowance for both AS and PsA patients following biologic initiation.ConclusionThis real-world descriptive study confirms that patients treated with biologics have reduced disability and time off work despite being initiated ∼13 years after the first symptoms and 6 years after diagnosis.
published_date 2021-06-27T04:15:21Z
_version_ 1763754033181360128
score 10.997956

Similar Items